Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?

Posted by ABMN Staff on Mar 28th, 2025

Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.64 and traded as low as $2.66. Evoke Pharma shares last traded at $2.79, with a volume of 11,492 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Evoke Pharma in a report on Friday. They issued a “sell” rating for the company.

Get Our Latest Stock Analysis on Evoke Pharma

Evoke Pharma Stock Down 3.1 %

The firm has a 50-day moving average of $4.28 and a two-hundred day moving average of $4.64. The company has a market capitalization of $4.17 million, a PE ratio of -0.25 and a beta of 0.12.

Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). The business had revenue of $3.31 million for the quarter, compared to analysts’ expectations of $3.08 million. Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC boosted its stake in Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) by 163.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the period. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 at the end of the most recent quarter.

Evoke Pharma Company Profile

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.